Characteristics of mukoviscisidosis in the southern regions of Russia

Introduction. Cystic fibrosis (CF) is a  hereditary disease with genetic heterogeneity and clinical polymorphism. Expanding the range of knowledge about the characteristics of the course of the disease in different regions is important to achieve the goal of improving the quality and life expectancy.

Purpose. Comparative analysis of the features of the course of CF in the subjects of the Southern Federal District, Stavropol Territory.

Methods. Data from the National Register of Patients of the RF MV 2016 were used. Results: there are clinical and genetic features between the regions of the Southern Federal District and the Stavropol Territory of the North Caucasus Federal District and in general with the Russian Federation. Analysis of the data showed differences in indicators: the proportion of patients aged ≥ 18 is the lowest in the Republic of Crimea (14.9%), in the Rostov region the lowest average age of patients (9.0 ± 6.3), and the lowest age of diagnosis 2.2 ± 3.1 years. Late terms of diagnosis were revealed in the Stavropol Territory (4.0 ± 8.0 years), but here there is one of the highest average age of CF patients (14.1 ± 11.5), the proportion of adult patients (23.3%) and the lowest allelic frequency of F508del, which is determined by the high number of patients with a “soft” genotype. There is a high proportion of patients with an undetermined genotype. A low proportion of two identified genetic variants of the CFTR gene is registered in patients of the Republic of Crimea. A low frequency of Burkholderia cepacia complex and Achromobacter spp was revealed, and a high infection with non-tuberculous mycobacteria was revealed in the Rostov region. FEV1 in children and adults was lower in Rostov Region and Stavropol Territory. In all regions, there is a discrepancy between the seeding of flora and azithromycin therapy and the severity of the genotype with the use of pancreatic enzymes.

Conclusions. Analysis of the data of the registry, which allows substantiating the need to study the regional characteristics of the course of CF in order to differentiate the planning of measures to improve the quality of medical care for patients with CF.

1. Kondratieva E.I., Kashirskaya N.Yu., Kapranova N.I. (eds.). National Consensus “Cystic Fibrosis: Definition, Diagnostic Criteria, Therapy”. 2nd ed. Moscow: BORGES; 2019. 356 p. (In Russ.) Available at: https://mukoviscidoz.org/doc/ konsensus/2019/konsensus-2019-bez-rentgenogramm.pdf.

2. Samsonova M.S., Simonova O.I., Vinyarskaya I.V. Opportunities of health utilities index questionnaire in the assessment of peculiarities of alterations of life quality of children with cystic fibrosis against the background of its management. Russian Pediatric Journal. 2016;(2):86–91. (In Russ.) Available at: https://cyberleninka.ru/article/n/osobennosti-izmeneniykachestva-zhizni-bolnyh-mukovistsidozom-na-fone-ego-effektivnogolecheniya/pdf.

3. Kapranov N.I., Kashirskaya N.Yu., Tolstova V.D. Early diagnosis and adequate treatment of children with cystic fibrosis in the Russian Federation. Gastroenterology of St Petersburg. 2008;(2–3):14–16. (In Russ.) Available at: http://gastroforum.ru/wp-content/uploads 2013/07/gsp_2-3_2008_14-16.pdf.

4. Casier A., Goubert L., Theunis M., Huse D., De Baets F., Matthys D., Crombez G. Acceptance and well-being in adolescents and young adults with cystic fibrosis: a prospective study. J Pediatr Psychol. 2011;36(4):476–487. https://doi.org/10.1093/jpepsy/jsq111.

5. Kapranov N.I., Kashirskaya N.Yu. (eds.). Cystic fibrosis. Moscow: Medpraktika-M; 2014. 672 p. (In Russ.) Available at: https://gamaleya.org/about/elektronnayabiblioteka/otdelnye-izdaniya/1192/.

6. Kapranov N., Kondratieva E., Sherman .V. Modern diagnosis and treatment of cystic fibrosis. Meditsinskiy Sovet. 2014;(8):44–49. (In Russ.) https://doi. org/10.21518/2079-701X-2014-8-44-49.

7. Dodge J.A., Lewis P.A., Stanton M., Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J. 2007;29(3):522–526. https://doi.org/10.1183/09031936.00099506.

8. Kapranov N.I., Kashirskaya N.Yu. Improvement of Medical and Social Help Organization for Cystic Fibrosis Patients in the Modern Period in Russia. Lechebnoe Delo. 2010;(2):12–17. (In Russ.) Available at: https://cyberleninka.ru/article/n/problemy-organizatsii-i-sovershenstvovaniya-meditsinskoyi-sotsialnoy-pomoschi-bolnym-mukovistsidozom-v-rossii-nasovremennom-etape/viewer.

9. Castellani C., Duff A.J.A., Bell S.C., Heijerman H.G.M., Munck A., Ratjen F. et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153–178. https://doi.org/10.1016/j.jcf.2018.02.006.

10. Krasovsky S., Cherniak A., Amelina E., Voronkova A.Yu. 372 Survival analysis of cystic fibrosis (CF) patients in the Moscow region of Russia in 2000– 2010. J Cyst Fibr. 2011;10(1):S95. http://doi.org/10.1016/S1569- 1993(11)60384-6.

11. Kapranov N.I., Kashirskaya N.Yu. (eds.). Cystic fibrosis. Modern achievements and current problems. 4th ed. Moscow: Medical Genetic Research Center of the Russian Academy of Medical Sciences; 2011. 124 p. (In Russ.) Available at: https://www.studmed.ru/kapranov-n-i-kashirskaya-n-yu-i-dr-mukoviscidozsovremennye-dostizheniya-i-aktualnye-problemy_6ce1fc0f359.html.

12. Baranov A.A., Kapranov N.I., Kashirskaya N.Yu., Namazova-Baranova L.S., Sherman V.D., Simonova O.I. et al. Diagnostic problems of mucoviscidosis and ways of solution in russia. Pediatric Pharmacology. 2014;(6):16–23. (In Russ.) https://doi.org/10.15690/pf.v11i6.1211.

13. Krasovskiy S.A., Amelina E.L., Gorinova U.V., Chernyak A.V., Afanasjeva M.V., Krilova N.A. et al. Тhe Dynamics of Some Indicators of the Health of Adult Patients with Cystic Fibrosis, Observedin the Research Institute of Pulmonology in 2003–2018. Journal of Clinical Practice. 2018;(4):25–32 (In Russ.) Available at: https://journals.eco-vector.com/clinpractice/article/ view/10591/8622.

14. Krasovsky S.A., Amelina E.L., Chernyak A.V., Kashirskaya N.Yu., Nikonova V.S., Voronkova A.Yu. et al. A role of Moscow regional register for management of cystic fibrosis patients. Pulmonologiya. 2013;(2):27–32. (In Russ.) https://doi.org/10.18093/0869-0189-2013-0-2-27-32.

15. Krasovsky S.A., Chernyak A.V., Voronkova A.Yu., Amelina E.L., Kashirskaya N.Yu., Kondratieva E.I. et al. (eds.). Register of patients with cystic fibrosis in the Russian Federation. 2016. Moscow: Medpraktika-M; 2018. 64 p. (In Russ.) Available at: https://mukoviscidoz.org/doc/registr/Registre_2016%20ctp.pdf.

16. Asherova I.K., Kapranov N.I. The register as a means of improving the quality of mucoviscidosis patients’ treatment. Pediatric Pharmacology. 2012;(3):96–101. (In Russ.) https://doi.org/10.15690/pf.v9i3.330.

17. Krasovsky S.A., Chernyak A.V., Amelina E.L., Nikonova V.S., Voronkova A.Yu., Samoilenko V.A. et al. Survival trends of cystic fibrosis patients in Moscow and Moscow region in 1992–2001 and 2002–2011. Pulmonologiya. 2012;(3):79–86. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-3-79-86.

18. Krasovskii S.A., Nikonova V.S., Kashirskaya N.Yu., Kondrat’eva E.I., Chernyak A.V., Kapranov N.I. et al. Clinical and genetic, microbiological and functional characteristics of moscow and moscow region patients with cystic fibrosis. Current Pediatrics. 2013;(1):17–23. (In Russ.) https://doi. org/10.15690/vsp.v12i1.554.

19. Kondrateva E.I., Krasovskiy S.A., Ilenkova N.A., Chikunov V.V., Voronkova A.Yu., Chernyak A.V. et al. Comparative characteristics of patients with cystic fibrosis, residing in Central European Russia and Siberia. Pediatria. 2017;96(2):158–163. (In Russ.) Available at: https://pediatriajournal.ru/ archive?show=357&section=4887&.

20. Vodovozova E.V., Ledeneva L.N., Kapranov N.I., Ponomareva T.A., Polyakova I.V., Pustabaeva M.S. et al. Organization of aid in cystic fibrosis patients in the north-caucasian Federal Region. Russian Pediatric Journal. 2017;(2):84–88. (In Russ.) Available at: https://cyberleninka.ru/article/n/ organizatsiya-pomoschi-bolnym-mukovistsidozom-v-severo-kavkazskomfederalnom-okruge/pdf.

21. Vodovozova E.V., Ledeneva L.N., Grigoriants I.S., Enina Е.А. Microflora of the respiratory tract in children with cystic fibrosis of the stavropol territory. Medical News of North Caucasus. 2020;(2):192–194. (In Russ.) https://doi.org/10.14300/mnnc.2020.15046.

22. Debray D., Kelly D., Houwen R., Strandvik B., Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10(2 Suppl.):S29–S36. https://doi. org/10.1016/s1569-1993(11)60006-4.

23. Smyth A.R., Bell S.C., Bojcin S., Bryon M., Duff A., Flume P. еt al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014;13(1 Suppl.):S23–S42. https://doi.org/10.1016/j.jcf.2014.03.010.

24. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40. Available at: https://pubmed.ncbi.nlm. nih.gov/8499054.

25. George P.M., Banya W., Pareek N., Bilton D., Cullinan P., Hodson M.E., Simmonds N.J. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. BMJ. 2011;342:d1008. https://doi. org/10.1136/bmj.d1008.

26. Smirnov I.E., Tarasova O.V., Lukina O.F., Kustova O.V., Sorokina T.E., Cimonova O.I. Structural and functional state of the lungs in cystic fibrosis in children. Russian Pediatric Journal. 2015;(2):11–17. (In Russ.) Available at: https://cyberleninka.ru/article/n/strukturno-funktsionalnoesostoyanie-legkih-pri-mukovistsidoze-u-detey/viewer.

27. Lee T.W.R., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29–34. https://doi. org/10.1016/S1569-1993(02)00141-8.

28. Zemanick E.T., Sagel S.D., Harris J.K. The airway microbiome in cystic fibrosis and implication for treatment. Curr Opin Pediatr. 2011;23(3):319–324. https://doi.org/10.1097/mop.0b013e32834604f2.

29. Riordan J.R., Rommens J.M., Kerem B., Alon N., Rozmahel R., Grzelczak Z. et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066–1073. https://doi.org/10.1126/science.2475911.

30. Castellani C. Cuppens H., Macek M. Jr., Cassiman J.J., Kerem E., Durie P. et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7(3):179–196. https://doi. org/10.1016/j.jcf.2008.03.009.

31. Petrova N.V., Kondratyeva E.I., Krasovsky S.A., Polyakov A.V., Ivachshenko T.E., Pavlov A.E. et al National Consensus Project «Cystic fibrosis: definition, diagnostic criteria, treatment» Section «Genetics of Cystic Fibrosis. Molecular genetic diagnosis of cystic fibrosis». Medical Genetics. 2016;15(11):29–45. (In Russ.) Available at: https://www.medgenjournal.ru/jour/article/view/188.

32. Krasovskiy S.A., Kashirskaya N.Yu., Chernyak A.V., Amelina E.L., Petrova N.V., Polyakov A.V. et al. Genetic characterization of cystic fibrosis patients in Russian Federation according to the National Register, 2014. Pulmonologiya. 2016;(2):133–151. (In Russ.) https://doi.org/10.18093/0869- 0189-2016-26-2-133-151.